KINDERHOOK, N.Y. - December 29, 2015 - American Bio Medica Corporation (OTCPK:ABMC) announced today that they have completed the research and development of a new rapid urine drug test that will detect compounds found in synthetic marijuana; commonly known as 'K2'or 'Spice'. The new test will detect JWH-018 and JWH-073, two of the most common compounds found in synthetic marijuana products. The test will also indicate positive or negative results for 16 additional cross-reacting compounds at certain cut-off levels. JWH-073 can be detected as low as 25 ng/ml, the lowest detection level available on the market today.
ABMC's Chief Executive Officer Melissa A. Waterhouse stated, 'This test for K2 will compliment our existing product lines; it is fast, easy to use, cost effective and it will provide our customers with the level of quality they are used to getting with ABMC products. We have no doubt it will be the most effective rapid K2 detection tool on the market.'
The K2 test will be marketed in the United States for forensic use only. The Company is accepting pre-orders, and the test will be available for shipment to ABMC customers in early 2016.
For more information on ABMC or its drug testing products, please visit www.abmc.com.
About American Bio Medica Corporation
American Bio Medica Corporation develops, manufactures and markets accurate, cost-effective immunoassay test kits, primarily point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen®, Rapid ONE®, RDS® InCup®, Rapid TOX® and Rapid TOX Cup® II test for the presence or absence of drugs of abuse in urine, while OralStat® and Rapid STAT™ test for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader® is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.
American Bio Medica Corporation Melissa A. Waterhouse Chief Executive Officer (800) 227-1243, Ext 107
American Bio Medica Corporation issued this content on 2015-12-29 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 2016-01-07 19:05:27 UTC
Original Document: http://www.abmc.com/investor/news/abmc_news_151229.html
